A shadow market for unapproved slimming drugs is being driven by TikTok fitness influencers and sellers on messaging platforms, according to new investigations.
Experimental Treatment Acquiring Traction Via Social Media
Retatrutide, which is still in research studies, is being promoted by social media influencers for its supposed fat-burning effects. Viewers are urged to contact these accounts directly for supplier links, while also obtaining promotional offers.
Thriving Trade on Messaging Platforms
Separately, a flourishing market exists on messaging services, where groups with thousands of participants share comparison images, administration instructions and claims of next-day UK delivery. Sellers promote the drug there before directing customers to WhatsApp for purchases.
Understanding Retatrutide
Retatrutide is an investigational injectable developed by US drugmaker Eli Lilly. The drug targets three intestinal hormones – GLP-1, GIP and glucagon. Early trials indicate it could assist patients reduce up to a quarter of their body weight. Referred to as the “triple G”, the drug is being promoted online as the next Ozempic.
Medical Experts Express Concerns
However, physicians and pharmacists have warned that the distribution of what is still an unapproved drug in the UK is worrisome and could lead to users administering products of uncertain source.
Some experts said the popularity for the experimental drug could be linked to the rising price of licensed slimming treatments such as Mounjaro.
Legal Position and Implementation
Marketing the unapproved drug on TikTok or Telegram is prohibited in the United Kingdom, as it is an unlicensed drug that cannot be promoted or supplied for personal consumption under the British medical regulations.
Some content creators try to sidestep the regulations by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but advertising and distribution can still breach pharmaceutical, marketing, and customer regulations, risking penalties, legal action or prison.
Service Reaction and Content Elimination
Based on the social media company, the service has taken down problematic content and banned associated hashtags and query recommendations. The company stated it was committed to maintaining the platform safe and investing in enhancing compliance measures.
Online Trading Activities
Research also discovered communities with up to 9,000 members selling retatrutide using Telegram's integrated discovery tool, which functions like a online catalog. Entering “retatrutide” immediately displays channels with numerous of users, filled with photos of weight loss, positive reviews and detailed guides for preparing or injecting at residence.
Within moments of entering one community, a vendor posted WhatsApp details, where most purchases take place. The seller sent an guidebook and promised delivery within 48 hours. When asked whether the product was authentic, one vendor responded: “You can’t be sure.” Another provided a image of a alleged testing documentation. None inquired about body mass, medical conditions or past usage.
Product Details and Costs
Within these groups, posts show black plastic parcels with Royal Mail labels, claiming to contain fresh supplies. One message stated: “It took eight of us to load them this morning.”
Customers can select between powder vials, mixed at residence with purified liquid, or ready-to-use injectors usually sold at £160 for 20mg. When questioned how much time a pen should be used, vendors give conflicting responses ranging from a few weeks to “depends on your body”.
Service Moderation and Security Actions
A spokesperson for Telegram said it actively monitored harmful material on its service including content that promoted the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Warnings
“Individuals are administering substances they can’t verify. Even if the science behind retatrutide is valid, these online products may not include what they advertise,” said Jason Murphy, the director of pharmacy at a pharmacy service.
A medical professional of an online medical service linked the surge in interest to current cost increases for approved weight-loss medications such as Mounjaro. “With costs rising, patients are using social media. But fake treatments are extremely dangerous. You can’t be certain what’s contained or whether the conditions they were made in was sterile,” she said.
Her team has previously seen patients injured by personal administration from unconfirmed suppliers. “We recognize the frustration, but buying from messaging apps or communication platforms is gambling with your well-being,” said the doctor. “These substances could be contaminated or incorrectly dosed.”
Producer Position
A representative from Eli Lilly said the substance was in phase 3 clinical trials and had not been evaluated or approved by any regulatory agency anywhere in the world. “Consequently at this time no one can market [it] for human use,” they said, adding that any product “falsely representing itself as a company investigational product not yet approved … may expose patients to possibly significant health risks”.
